References in periodicals archive ?
More than one million hospitalizations of patients with acute congestive heart failure as the primary diagnosis occur in the United States each year.
Nasdaq: SCIO) today announced the initiation of a new study aimed at investigating the potential pharmacoeconomic impact of its lead drug candidate, Natrecor(R) (nesiritide), in improving treatment and outcomes for acute congestive heart failure patients.
Nasdaq: SCIO) announced today presentations that will be made about its investigational new drug, Natrecor(R) (nesiritide) for acute congestive heart failure at the 50th Annual Scientific Sessions of the American College of Cardiology in Orlando, Florida.
If approved, Natrecor would be the first new therapy for acute congestive heart failure in more than a decade.

Full browser ?